Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice

Author：            

Publisher： Spandidos Publications

ISSN： 1792-0981

Source： Experimental and Therapeutic Medicine, Vol.4, Iss.6, 2012-01, pp. : 987-992

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation

By              

Molecular Medicine Reports, Vol. 8, Iss. 2, 2013-01 ,pp. : 439-445

Spandidos Publications

Access to resources Recommend Favorite

Association between metabolic syndrome and the development of non-alcoholic fatty liver disease

By            

Experimental and Therapeutic Medicine, Vol. 6, Iss. 1, 2013-01 ,pp. : 77-84

Spandidos Publications

Access to resources Recommend Favorite

A case–control study of non-alcoholic fatty liver disease in breast cancer

By Bilici Ahmet   Ozguroglu Mustafa   Mihmanlı İsmail   Turna Hande   Adaletli İbrahim  

Medical Oncology, Vol. 24, Iss. 4, 2007-12 ,pp. : 367-371

Humana Press, Inc

Access to resources Recommend Favorite

Ezetimibe prevents the development of nonalcoholic fatty liver disease induced by highfat diet in C57BL/6J mice

By  

Molecular Medicine Reports, Vol. 10, Iss. 6, 2014-01 ,pp. : 2917-2923

Spandidos Publications

Access to resources Recommend Favorite

Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-α and SREBP-1c

By        

Molecular Medicine Reports, Vol. 6, Iss. 4, 2012-01 ,pp. : 815-820

Spandidos Publications

Access to resources Recommend Favorite